NCT03220178View on ClinicalTrials.gov

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

PHASE4TerminatedINTERVENTIONAL
Enrollment

532

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
Breast Neoplasm
Interventions
DRUG

Palbociclib

Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle

DRUG

Fulvestrant

500mg per use-after first application, again at wk2, then once per month

DRUG

Anastrozole

1mg per day

DRUG

Letrozole

2,5mg/day

DRUG

Exemestane

25mg/day

Trial Locations (1)

55131

University Hospital Mainz, Mainz

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

WSG WOMEN´S HEALTHCARE STUDY GROUP

UNKNOWN

collaborator

Cankado GmbH

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

AGO-TraFo

UNKNOWN

collaborator

AGO-B

UNKNOWN

collaborator

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.

UNKNOWN

lead

Palleos Healthcare GmbH

INDUSTRY

NCT03220178 - Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | Biotech Hunter | Biotech Hunter